Skip to Content
Merck
  • Yakult: a role in combating multi-drug resistant Pseudomonas aeruginosa?

Yakult: a role in combating multi-drug resistant Pseudomonas aeruginosa?

Journal of wound care (2013-02-16)
C H Thomson, I Hassan, K Dunn
ABSTRACT

Presence of extremely drug resistant metallo-beta-lactamase (MBL VIM) Pseudomonas aeruginosa in a patient presenting with 54% deep-dermal and full-thickness flame burns to her neck, chest, upper abdomen and upper limbs, appeared to coincide with wound breakdown and non-healing. This organism was also seen to colonise the patient's gastrointestinal tract, which was thought to act as a reservoir for re-infection of her wounds. Oral treatment with a probiotic drink (Yakult yoghurt) was commenced in order to alter gut flora. Two weeks after this regimen began, P. aeruginosa grown from wound swabs was seen to change from multi-drug resistant to multi-drug sensitive strains. This change persisted through to patient discharge home from hospital. The temporal relationship seen between commencement of once-daily probiotic and change of the organism from multi-drug resistant to multi-drug sensitive suggests that this may have been an effective intervention.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Penicillinase from Bacillus cereus, lyophilized powder, 1,500-3,000 units/mg protein (using benzylpenicillin)
Sigma-Aldrich
β-Lactamase from Enterobacter cloacae, Type IV, lyophilized powder, 0.2-0.6 units/mg protein (using benzylpenicillin)
Sigma-Aldrich
Penicillinase from Bacillus cereus, lyophilized, powder, white, ~13 U/mg
Sigma-Aldrich
β-Lactamase, recombinant, expressed in E. coli
Sigma-Aldrich
β-Lactamase from Pseudomonas fluorescens, lyophilized powder, recombinant, expressed in E. coli